Pelthos Therapeutics Inc Receivables Turnover Ratio (PTHS), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Pelthos Therapeutics Inc   (NYSEAMER: PTHS)
 

Pelthos Therapeutics Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Pelthos Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 4.03, this represents a new company high. This is a clear indication for improving liquidity at Pelthos Therapeutics Inc 's clients. Average receivable collection period, for the Pelthos Therapeutics Inc in Jun 30 2026 quarter, has decreased to 91 days, compared to 94 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 437 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Pelthos Therapeutics Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTHS Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change - - - - -
Receivable Turnover Ratio (TTM) 4.03 3.88 3.99 3.71 -
PTHS's Total Ranking # # # # #
Accounts Receivable average collection period days 91 94 92 98 -
Seq. Receivable Change 23.78 % 32.08 % 10.89 % - -
Seq. Revenue Change 43.07 % 16.16 % 26.78 % - -


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 45
Healthcare Sector # 438
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
4.03 4.03 4.03
(Jun 30 2026)  





PTHS Company Profile • Back to PTHS Efficiency Comparisons • Compare PTHS Receivables Turnover Ratio to its Competitors

Financial Statements
Pelthos Therapeutics Inc 's Accounts Receivable $ 14 Millions Visit PTHS's Balance sheet
Pelthos Therapeutics Inc 's Sales TTM $ 43 Millions Visit PTHS's Income Statement
Sources of PTHS's Revenues Visit PTHS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PTHS's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PTHS's Growth Rates PTHS's Roa PTHS's Inventory Turnover Ratio PTHS's Dividend Comparisons
PTHS's Profitability Ratios PTHS's Roi PTHS's Asset Turnover Ratio PTHS's Dividend Growth
PTHS's Valuation Ratios PTHS's Roe PTHS's Financial Strength Ratios PTHS's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Madrigal Pharmaceuticals Inc   8.19 $ 1,283.940  Millions$ 156.857  Millions
X4 Pharmaceuticals Inc  8.17 $ 9.441  Millions$ 1.156  Millions
Seastar Medical Holding Corp  8.11 $ 1.713  Millions$ 0.211  Millions
Atricure Inc   8.08 $ 567.747  Millions$ 70.232  Millions
Concentra Group Holdings Parent Inc   8.07 $ 2,287.465  Millions$ 283.300  Millions
Penumbra Inc  8.06 $ 1,504.874  Millions$ 186.788  Millions
Sanuwave Health Inc   8.04 $ 43.903  Millions$ 5.461  Millions
Sight Sciences Inc   8.04 $ 83.351  Millions$ 10.368  Millions
Aveanna Healthcare Holdings Inc   8.03 $ 2,602.820  Millions$ 324.026  Millions
Avita Medical Inc   7.99 $ 75.631  Millions$ 9.463  Millions
Koru Medical Systems Inc   7.97 $ 45.108  Millions$ 5.658  Millions
Alphatec Holdings Inc   7.94 $ 814.780  Millions$ 102.662  Millions
Safe Pro Group Inc   7.94 $ 2.881  Millions$ 0.363  Millions
Henry Schein Inc   7.91 $ 13,602.000  Millions$ 1,719.000  Millions
Tela Bio Inc   7.86 $ 80.535  Millions$ 10.243  Millions
Exelixis Inc   7.81 $ 2,435.920  Millions$ 311.950  Millions
Castle Biosciences Inc   7.79 $ 357.278  Millions$ 45.867  Millions
Trisalus Life Sciences Inc   7.78 $ 45.179  Millions$ 5.808  Millions
Idexx Laboratories Inc  7.75 $ 4,553.792  Millions$ 587.472  Millions
Vycor Medical Inc   7.68 $ 1.807  Millions$ 0.235  Millions
Aurinia Pharmaceuticals Inc   7.67 $ 311.507  Millions$ 40.624  Millions
Beta Bionics Inc   7.65 $ 119.513  Millions$ 15.615  Millions
Lemaitre Vascular Inc   7.65 $ 262.923  Millions$ 34.370  Millions
Novocure Limited  7.62 $ 699.193  Millions$ 91.768  Millions
Natera Inc   7.61 $ 2,707.077  Millions$ 355.618  Millions
Co diagnostics Inc   7.58 $ 0.721  Millions$ 0.095  Millions
Quest Diagnostics Inc  7.56 $ 11,560.000  Millions$ 1,529.250  Millions
Edap Tms Sa  7.55 $ 111.051  Millions$ 14.699  Millions
Fortress Biotech Inc   7.55 $ 69.983  Millions$ 9.266  Millions
Protalix Biotherapeutics inc   7.55 $ 80.619  Millions$ 10.677  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.